TPST实时信号 | 通过Getagraph.com最大化利润

出售 105267 min ago

@ $4.10

发出时间: 14 Feb 2024 @ 22:30

回报率: -13.66%

上一信号: Feb 13 - 22:30

上一信号: 购买

回报率: -0.93 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	402 127
平均成交量	979 955
市值	78.65M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-0.440 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0.0120 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Brady Stephen R	Buy	250 000	Employee Stock Option (right to buy)
2024-01-03	Whiting Samuel	Buy	100 000	Employee Stock Option (right to buy)
2024-01-03	Trojanowski Justin	Buy	26 500	Employee Stock Option (right to buy)
2024-01-03	Maestas Nicholas	Buy	40 000	Employee Stock Option (right to buy)
2023-10-11	Brady Stephen R	Buy	725 000	Employee Stock Option (right to buy)

INSIDER POWER
99.69
Last 85 transactions
Buy: 12 322 880 \| Sell: 50 340

音量相关性

長: 0.01 (neutral)

短: -0.68 (moderate negative)

Signal:(42.86) Neutral

Tempest Therapeutics, 相关性

10 最正相关
SIFY	0.842
SVOK	0.816
FORE	0.814

10 最负相关
RAVN	-0.856

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tempest Therapeutics, 相关性 - 货币/商品

0.59
( weak )

0.56
( weak )

0.00
( neutral )

0.32
( neutral )

Tempest Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2023
营收:	$0
毛利润:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2022
营收:	$0
毛利润:	$-1.81M (0.00 %)
EPS:	$-3.18

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.27

Financial Reports:

No articles found.

Tempest Therapeutics,

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.